Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02231723 · ClinicalTrials.gov registry record · Phase 1

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

A Phase 1 study, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 1
Development phase
139
Enrollment target

NCT02231723: Completed Phase 1 study, sponsored by Sumitomo Pharma America.

NCT02231723 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 139 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (132% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02231723, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 1
Development phase
139 participants
Enrollment target

Study Summary

This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.

Interventions

  • DRUG Leucovorin
  • DRUG Oxaliplatin
  • DRUG Gemcitabine
  • DRUG Nab-paclitaxel
  • DRUG BBI608

Trial Details

FieldValue
Enrollment Target 139 participants
Start Date 2014-08
Est. Completion 2020-06
Phase Phase 1
Sumitomo Pharma America

168 total trials

What the finished NCT02231723 record still lists

NCT02231723 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (132% higher).

The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.

NCT02231723 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02231723 about?

NCT02231723 is a clinical study titled "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer". This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.

What is the current status of trial NCT02231723?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2014-08. Estimated completion is 2020-06.

What interventions are being tested in trial NCT02231723?

The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), BBI608 (DRUG).

Who is sponsoring clinical trial NCT02231723?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02231723's enrollment target sits among peer trials

139 418th of 2000 higher than 1,583 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05645380 · 139 participants · Phase 2

    Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

  • NCT06239272 · 139 participants · Phase 1

    NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • NCT06252220 · 139 participants · Phase 1

    First in Human Study in Subjects With Obesity, But Otherwise Healthy

  • NCT06537128 · 139 participants · NA

    Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02231723, the US trial registry maintained by the National Library of Medicine. NCT02231723 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.